Physician profile
David Levine
NPI 1720004708
$13,507.90
in general payments reported to CMS, 2019-2025
46 companies · $2,411 in 2025
The $2,411 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,374 · 2020: $1,267 · 2021: $1,334 · 2022: $1,594 · 2023: $1,848 · 2024: $1,680 · 2025: $2,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,939.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,455.87 | 2019-2025 | Farapulse, Rhythmia Mapping System, Watchman Access System |
| Medtronic, INC. | $2,208.82 | 2021-2025 | Linq II, Corevalve Evolut R, Micra |
| Medtronic Vascular, INC. | $1,599.54 | 2019-2020 | |
| Abbott Laboratories | $1,508.06 | 2019-2025 | Ensite, Aveir, Jot Dx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $901.90 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $770.70 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $637.71 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $609.22 | 2019-2024 | Camzyos, Eliquis |
| Pfizer INC. | $512.21 | 2019-2025 | |
| Cardiva Medical, INC. | $428.03 | 2021-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Philips North America LLC | $182.82 | 2020-2025 | (Ck4) Mcot, Extended Holter, Event |
| Amarin Pharma, INC. | $152.02 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $140.91 | 2020-2024 | Farxiga |
| Biotronik INC. | $120.40 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $117.43 | 2022-2025 | Verquvo, Belsomra |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $110.55 | 2021-2022 | |
| Amgen INC. | $99.70 | 2019-2023 | Repatha |
| Inspire Medical Systems, INC. | $87.55 | 2024-2025 | Inspire |
| Novo Nordisk INC | $63.01 | 2024-2025 | Ozempic |
| Elutia, INC. | $55.50 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $53.26 | 2022-2024 | |
| Chiesi USA, INC. | $48.74 | 2019-2022 | |
| Smith+Nephew, INC. | $45.42 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $40.63 | 2021-2024 | Onpattro |
| Lexicon Pharmaceuticals, INC. | $38.85 | 2023 | Inpefa |
| Ethicon US, LLC | $38.15 | 2025 | Vistaseal |
| Kiniksa Pharmaceuticals, Ltd. | $34.79 | 2021-2022 | |
| Silk Road Medical, INC. | $31.81 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Regeneron Healthcare Solutions, INC. | $31.59 | 2019 | |
| Bardy Diagnostics, INC. | $30.63 | 2019-2020 | |
| Braemar Manufacturing, LLC | $30.25 | 2019 | |
| Bridgebio Pharma, INC. | $29.73 | 2025 | Attruby |
| Ge Healthcare | $29.63 | 2024 | |
| Edwards Lifesciences Corporation | $28.47 | 2019 | |
| Biosense Webster, INC. | $24.41 | 2024 | Carto 3 |
| Cvrx, INC. | $24.39 | 2024 | Barostim Neo System |
| Stryker Corporation | $24.21 | 2021 | |
| Baxter Healthcare | $21.06 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Vital Connect, INC | $20.79 | 2023 | Vitalpatch Rtm |
| Itamar Medical INC | $20.62 | 2022 | |
| Lundbeck LLC | $19.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.61 | 2024 | Jardiance |
| Arbor Pharmaceuticals, INC. | $17.15 | 2021 | |
| Medline Industries Lp | $15.94 | 2025 | |
| Abiomed | $15.34 | 2025 | |
| Teleflex LLC | $13.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.